Alto Neuroscience Inc.
ANRO | NYSE
$30.41
-$0.22 (-0.72%)
Sep 22, 2026, 12:46 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 184K | n/a | n/a | 100K | n/a | 170K | n/a | n/a | 97K | 92K | n/a | 100K | 86K | 97K |
Gross Profit | n/a | -184K | n/a | n/a | -100K | n/a | -170K | n/a | n/a | -97K | -92K | n/a | -100K | -86K | -97K |
Operating Income | -29.13M | -27.14M | 115.67M | -14.95M | -18.68M | -15.68M | -17M | -18.89M | -18.34M | -14.39M | -11.77M | -9.72M | -9.13M | -7.2M | -8.06M |
Interest Income | 2.11M | 1.56M | 1.56M | 1.53M | 1.68M | 1.83M | 2.14M | 2.5M | 2.66M | 1.56M | 738K | 714K | 667K | 230K | 112K |
Pretax Income | -27.64M | -26.24M | -16.18M | -14.18M | -17.71M | -15.17M | -15.2M | -16.78M | -16.03M | -13.42M | -11.22M | -9.14M | -8.66M | -7.28M | -7.65M |
Net Income | -27.64M | -26.24M | -16.18M | -14.18M | -17.71M | -15.17M | -15.2M | -16.78M | -16.03M | -13.42M | -11.22M | -9.14M | -8.66M | -7.28M | -7.65M |
Selling & General & Admin | 7.02M | 6.84M | 5.06M | 4.43M | 5.56M | 5.7M | 6.03M | 5.83M | 5.16M | 4.34M | 2.03M | 1.75M | 1.95M | 1.51M | 1.64M |
Research & Development | 22.11M | 20.29M | 12M | 10.53M | 13.12M | 9.97M | 10.8M | 13.06M | 13.18M | 9.95M | 9.64M | 7.97M | 7.07M | 5.61M | 6.32M |
Other Expenses | n/a | -184K | -132.73M | n/a | -100K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 29.13M | 26.95M | -115.67M | 14.95M | 18.58M | 15.68M | 16.83M | 18.89M | 18.34M | 14.29M | 11.67M | 9.72M | 9.03M | 7.12M | 7.96M |
Interest Expense | 491K | 545K | 575K | 650K | 646K | 598K | 333K | 349K | 347K | 346K | 356K | 363K | 327K | 324K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -97K | n/a | n/a | -100K | -86K | -97K |
Cost & Expenses | 29.13M | 27.14M | -115.67M | 14.95M | 18.68M | 15.68M | 17M | 18.89M | 18.34M | 14.39M | 11.77M | 9.72M | 9.13M | 7.2M | 8.06M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 42.81M | 32.89M | 31.92M | 27.1M | 27.07M | 27.05M | 26.99M | 26.96M | 26.95M | 26.88M | 26.88M | 26.88M | 26.88M | 26.88M | 25.57M |
Shares Outstanding (Diluted) | 42.81M | 32.89M | 31.92M | 27.1M | 27.07M | 27.05M | 26.99M | 26.96M | 26.95M | 26.88M | 26.88M | 26.88M | 26.88M | 26.88M | 25.57M |
EPS (Basic) | -0.65 | -0.80 | -0.51 | -0.52 | -0.65 | -0.56 | -0.56 | -0.62 | -0.59 | -0.50 | -0.42 | -0.34 | -0.32 | -0.27 | -0.30 |
EPS (Diluted) | -0.65 | -0.80 | -0.51 | -0.52 | -0.65 | -0.56 | -0.56 | -0.62 | -0.59 | -0.50 | -0.42 | -0.34 | -0.32 | -0.27 | -0.30 |
EBITDA | -27.15M | -25.51M | -15.45M | -13.37M | -16.96M | -14.4M | -14.7M | -16.31M | -15.57M | -12.97M | -10.77M | -8.72M | -8.24M | -6.87M | -7.56M |
EBIT | -27.15M | -25.69M | -15.61M | -13.53M | -17.06M | -14.57M | -14.87M | -16.43M | -15.68M | -13.07M | -10.86M | -8.78M | -8.34M | -6.96M | -7.65M |
Depreciation & Amortization | n/a | 184K | 157K | 164K | 100K | 171K | 170K | 122K | 113K | 97K | 92K | 63K | 100K | 86K | 97K |
Add to Watchlist
Select watchlists to add or remove ANRO